Form 4: Heron Therapeutics Executive Acquires Shares Through RSU Vesting

Heron Therapeutics' EVP and Chief Development Officer, William P. Forbes, acquired 3,874 shares of common stock through the vesting and conversion of restricted stock units.

Summary

• William P. Forbes, EVP, Chief Development Officer of Heron Therapeutics, Inc. (HRTX), acquired 3,874 shares of common stock.
• This acquisition resulted from the exercise or conversion of restricted stock units (RSUs) on July 19, 2025.
• Following this transaction, Mr. Forbes directly beneficially owns 138,940 shares of common stock.
• He also continues to hold 38,743 restricted stock units.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• The RSUs vest in 16 equal quarterly installments, with the vesting schedule commencing one quarter after the grant date of January 19, 2024.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-scheduled vesting of restricted stock units for a key executive, which is a neutral to slightly positive event as it increases the executive's direct ownership and aligns interests with shareholders. There are no unexpected positive or negative disclosures.

Positives

• The acquisition of shares by a key executive through RSU vesting indicates continued alignment of management's interests with shareholders.
• The transaction is part of a pre-scheduled vesting plan, reflecting a stable compensation structure.

Future Outlook

The remaining 38,743 restricted stock units will continue to vest in 16 equal quarterly installments, starting one quarter after the January 19, 2024 grant date.

Industry Context

This is a routine insider transaction related to executive compensation, common across publicly traded companies, and does not directly reflect broader industry trends.

Stakeholder Impact

• Shareholders: Increased direct ownership by a key executive may be viewed positively as it aligns management incentives with shareholder interests.
• Employees: Reflects standard executive compensation practices.

Next Steps

• Remaining restricted stock units will continue to vest in 16 equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled vesting of restricted stock units for a key executive. While it increases the executive's direct ownership, which is a positive for alignment, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's an expected event within the scope of executive compensation.

Keywords

Heron Therapeutics, HRTX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, William P. Forbes, Common Stock